812,876 Shares in Erasca, Inc. $ERAS Acquired by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management acquired 812,876 Erasca shares worth approximately $14.9 million, giving it a 0.26% stake. Institutional investors and hedge funds collectively own 67.78% of the company.
• Erasca shares opened at $18.12, while analysts’ average price target is $21.64 and the consensus rating is “Moderate Buy.” However, the company recently reported an adjusted loss of $0.60 per share, missing estimates of a $0.12 loss.
• The company faces investor lawsuits alleging misleading statements about its lead oncology candidate, ERAS-0015, while the appointment of Charles S. Fuchs as president of R&D is intended to strengthen its drug-development pipeline.

Assenagon Asset Management S.A. acquired a new stake in Erasca, Inc. (NASDAQ:ERAS - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 812,876 shares of the company's stock, valued at approximately $14,892,000. Assenagon Asset Management S.A. owned about 0.26% of Erasca at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in ERAS. Spruce Street Capital LP bought a new position in shares of Erasca in the 4th quarter valued at $14,469,000. Janus Henderson Group PLC bought a new position in Erasca in the first quarter valued at about $59,988,000. Commodore Capital LP acquired a new stake in shares of Erasca during the first quarter valued at about $51,372,000. Vivo Capital LLC boosted its stake in shares of Erasca by 31.0% during the first quarter. Vivo Capital LLC now owns 12,151,480 shares of the company's stock valued at $196,611,000 after purchasing an additional 2,878,052 shares in the last quarter. Finally, Siren L.L.C. grew its holdings in shares of Erasca by 28.4% during the first quarter. Siren L.L.C. now owns 11,244,246 shares of the company's stock worth $181,932,000 after purchasing an additional 2,486,997 shares during the last quarter. Institutional investors and hedge funds own 67.78% of the company's stock.

Erasca Stock Down 1.6%

Shares of ERAS stock opened at $18.12 on Tuesday. Erasca, Inc. has a 52 week low of $1.33 and a 52 week high of $24.28. The firm has a 50 day moving average of $16.89 and a 200-day moving average of $14.83. The company has a market cap of $5.63 billion, a price-to-earnings ratio of -19.48 and a beta of 0.66.

Erasca (NASDAQ:ERAS - Get Free Report) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.48). Analysts anticipate that Erasca, Inc. will post -0.54 earnings per share for the current year.

Erasca News Summary

Here are the key news stories impacting Erasca this week:

• Positive Sentiment: Erasca appointed internationally recognized medical oncologist Charles S. Fuchs, M.D., M.P.H. as president of R&D. The company said the appointment strengthens its drug-development leadership, which could support progress across its oncology pipeline, including ERAS-0015. Erasca Strengthens R&D Leadership
• Neutral Sentiment: Erasca investors face an August 10, 2026 deadline to seek lead-plaintiff status in a federal securities class action covering purchases made from January 14, 2025, through April 26, 2026. Multiple law firms issued substantially similar notices, increasing visibility around the litigation but not establishing liability. Rosen Erasca Investor Notice
• Negative Sentiment: The lawsuits and investigations allege that Erasca and certain executives misled investors about the competitive advantages, safety profile, and intellectual-property protection surrounding lead oncology candidate ERAS-0015. If the claims advance, the company could face legal costs, potential damages, management distraction, and additional scrutiny. Hagens Berman Erasca Class Action Notice
• Neutral Sentiment: Erasca is expected to report quarterly earnings on Tuesday. The results and management’s comments on ERAS-0015, the pipeline, cash resources, and the litigation could become the next major catalyst for ERAS shares. Erasca Expected Quarterly Earnings Release

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ERAS. HSBC set a $20.00 price objective on shares of Erasca in a report on Tuesday, July 14th. Mizuho cut their price target on shares of Erasca from $28.00 to $26.00 and set an "outperform" rating on the stock in a report on Tuesday, May 12th. Morgan Stanley increased their price objective on Erasca from $12.00 to $21.00 and gave the company an "equal weight" rating in a report on Monday, July 20th. Stifel Nicolaus lifted their target price on Erasca from $20.00 to $30.00 and gave the stock a "buy" rating in a report on Monday, April 27th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Erasca in a research report on Thursday, June 11th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Erasca has an average rating of "Moderate Buy" and an average target price of $21.64.

Erasca Company Profile

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca's approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca's pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.

Want to see what other hedge funds are holding ERAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Erasca, Inc. (NASDAQ:ERAS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source